Epigenetic Drugs As New Emerging Therapeutics: What Is the Scale's Orientation of Application and Challenges?

Epigenetic Drugs As New Emerging Therapeutics: What Is the Scale's Orientation of Application and Challenges? Publisher Pubmed

Farani MR¹ ; Sarlak M² ; Gholami A³ ; Azaraian M^{4, 5} ; Binabaj MM^{6, 7} ; Kakavandi S⁸ ; Tambuwala MM⁹ ; Taheriazam A^{10, 11} ; Hashemi M^{11, 12} ; Ghasemi S¹³

Show Affiliations

1. Toxicology and Diseases Group (TDG), Pharmaceutical Sciences Research Center (PSRC), the Institute of Pharmaceutical Sciences (TIPS), Tehran University of Medical Sciences, Tehran, 1417614411, Iran
2. Department of Chemistry, Portland State University, Portland, OR, United States
3. Student Research Committee, Kurdistan University of Medical Sciences, Sanandaj, Iran
4. Department of Radiology, Charite - Universitatsmedizin Berlin, Berlin, 10117, Germany
5. Department of Bioanalytical Ecotoxicology, UFZ â€“ Helmholtz Centre for Environmental Research, Leipzig, Germany
6. Clinical Biochemistry, Department of Biochemistry and Nutrition, School of Medicine, Sabzevar University of Medical Science, Sabzevar, Iran
7. Cellular and Molecular Research Center, Sabzevar University of Medical Sciences, Sabzevar, Iran
8. Department of Bacteriology and Virology, School of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran
9. Lincoln Medical School, University of Lincoln, Brayford Pool, Lincoln, LN6 7TS, United Kingdom
10. Department of Orthopedics, Faculty of medicine, Tehran Medical Sciences, Islamic Azad University, Tehran, Iran
11. Farhikhtegan Medical Convergence Sciences Research Center, Farhikhtegan Hospital Tehran Medical Sciences, Islamic Azad University, Tehran, Iran
12. Department of Genetics, Faculty of Advanced Science and Technology, Tehran Medical Sciences, Islamic Azad University, Tehran, Iran
13. Cancer Research Center, Shahrekord University of Medical Sciences, Shahrekord, Iran

Source: Pathology Research and Practice Published:2023

Abstract

Epigenetics is the study of heritable changes in gene expression or function without altering the DNA sequence. Important factors are part of epigenetic events, such as methylation, DNA histone rearrangements, nucleosome transposition, and non-coding RNAs. Dysregulated epigenetic mechanics are associated with various cancers' initiation, development, and metastasis. It is known that the occurrence and development of cancer can be controlled by regulating unexpected epigenetic events. Epi-drugs are used singly or in combination with chemotherapy and enhance antitumor activity, reduce drug resistance, and stimulate the host immune response. Despite these benefits, epigenetic therapy as a single therapy or in combination with other drugs leads to adverse effects. This review article introduces and compares the advantages, disadvantages, and side effects of using these drugs for the first time since their introduction. Also, this article describes the mechanism of action of various epigenetic drugs. Recommendations for future use of epigenetic drugs as cancer therapeutics are suggested as an overall conclusion. © 2023 Elsevier GmbH

Related Docs

View other Related Docs

1. Advances in Epigenetic Treatment of Adult T-Cell Leukemia/Lymphoma: A Comprehensive Review, Clinical Epigenetics (2025)

2. Epigenetic Targeting of Cancer Stem Cells by Polyphenols (Cancer Stem Cells Targeting), Phytotherapy Research (2021)

3. Targeting Epigenetics in Cancer: Therapeutic Potential of Flavonoids, Critical Reviews in Food Science and Nutrition (2021)

4. Epigenetic Regulation in Oral Squamous Cell Carcinoma Microenvironment: A Comprehensive Review, Cancers (2023)

5. Non-Coding Rnas in Leukemia Drug Resistance: New Perspectives on Molecular Mechanisms and Signaling Pathways, Annals of Hematology (2024)

6. Deciphering the Role of Loc124905135-Related Non-Coding Rna Cluster in Human Cancers: A Comprehensive Review, Heliyon (2024)

7. Epigenetic Modifications in Gastric Cancer: Focus on Dna Methylation, Gene (2020)

8. The Critical Role of Circular Rnas in Drug Resistance in Gastrointestinal Cancers, Medical Oncology (2023)

Experts (# of related papers)

View all Related Experts

Hamid Reza Mirzaei (2)

Amir Anushiravani (1)

Style	Citing Format
MLA	Farani MR, et al.. "Epigenetic Drugs As New Emerging Therapeutics: What Is the Scale's Orientation of Application and Challenges?." Pathology Research and Practice, vol. 248, no. , 2023, pp. -.
APA	Farani MR, Sarlak M, Gholami A, Azaraian M, Binabaj MM, Kakavandi S, Tambuwala MM, Taheriazam A, Hashemi M, Ghasemi S (2023). Epigenetic Drugs As New Emerging Therapeutics: What Is the Scale's Orientation of Application and Challenges?. Pathology Research and Practice, 248(), -.
Chicago	Farani MR, Sarlak M, Gholami A, Azaraian M, Binabaj MM, Kakavandi S, Tambuwala MM, Taheriazam A, Hashemi M, Ghasemi S. "Epigenetic Drugs As New Emerging Therapeutics: What Is the Scale's Orientation of Application and Challenges?." Pathology Research and Practice 248, no. (2023): -.
Harvard	Farani MR et al. (2023) 'Epigenetic Drugs As New Emerging Therapeutics: What Is the Scale's Orientation of Application and Challenges?', Pathology Research and Practice, 248(), pp. -.
Vancouver	Farani MR, Sarlak M, Gholami A, Azaraian M, Binabaj MM, Kakavandi S, et al.. Epigenetic Drugs As New Emerging Therapeutics: What Is the Scale's Orientation of Application and Challenges?. Pathology Research and Practice. 2023;248():-.
BibTex	@article{ author = {Farani MR and Sarlak M and Gholami A and Azaraian M and Binabaj MM and Kakavandi S and Tambuwala MM and Taheriazam A and Hashemi M and Ghasemi S}, title = {Epigenetic Drugs As New Emerging Therapeutics: What Is the Scale's Orientation of Application and Challenges?}, journal = {Pathology Research and Practice}, volume = {248}, number = {}, pages = {-}, year = {2023} }
RIS	TY - JOUR AU - Farani MR AU - Sarlak M AU - Gholami A AU - Azaraian M AU - Binabaj MM AU - Kakavandi S AU - Tambuwala MM AU - Taheriazam A AU - Hashemi M AU - Ghasemi S TI - Epigenetic Drugs As New Emerging Therapeutics: What Is the Scale's Orientation of Application and Challenges? JO - Pathology Research and Practice VL - 248 IS - SP - EP - PY - 2023 ER -

Science Communicator Platform

Authors

Authors Affiliations

Abstract